SCPH scPharmaceuticals Inc

Price (delayed)

$4.72

Market cap

$170.18M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.48

Enterprise value

$152.53M

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, ...

Highlights
The revenue rose by 30% since the previous quarter
scPharmaceuticals's gross profit has increased by 29% QoQ
The equity has plunged by 68% YoY and by 34% from the previous quarter
The company's quick ratio has shrunk by 66% YoY and by 15% QoQ

Key stats

What are the main financial stats of SCPH
Market
Shares outstanding
36.05M
Market cap
$170.18M
Enterprise value
$152.53M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.93
Price to sales (P/S)
10.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.65
Earnings
Revenue
$17.63M
EBIT
-$49.45M
EBITDA
-$48.87M
Free cash flow
-$60.49M
Per share
EPS
-$1.48
Free cash flow per share
-$1.55
Book value per share
$0.68
Revenue per share
$0.45
TBVPS
$2.01
Balance sheet
Total assets
$78.45M
Total liabilities
$53.89M
Debt
$40.8M
Equity
$24.57M
Working capital
$64.21M
Liquidity
Debt to equity
1.66
Current ratio
6.21
Quick ratio
5.21
Net debt/EBITDA
0.36
Margins
EBITDA margin
-277.2%
Gross margin
71.7%
Net margin
-327.3%
Operating margin
-338.6%
Efficiency
Return on assets
-58.7%
Return on equity
-132.4%
Return on invested capital
-66.5%
Return on capital employed
-74.8%
Return on sales
-280.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SCPH stock price

How has the scPharmaceuticals stock price performed over time
Intraday
4.19%
1 week
8.01%
1 month
14.01%
1 year
-43.54%
YTD
-24.72%
QTD
8.51%

Financial performance

How have scPharmaceuticals's revenue and profit performed over time
Revenue
$17.63M
Gross profit
$12.64M
Operating income
-$59.7M
Net income
-$57.71M
Gross margin
71.7%
Net margin
-327.3%
scPharmaceuticals's operating margin has soared by 83% YoY and by 17% from the previous quarter
SCPH's net margin has soared by 83% YoY and by 19% QoQ
scPharmaceuticals's operating income has decreased by 48% YoY and by 8% QoQ
scPharmaceuticals's net income has decreased by 43% YoY and by 5% QoQ

Growth

What is scPharmaceuticals's growth rate over time

Valuation

What is scPharmaceuticals stock price valuation
P/E
N/A
P/B
6.93
P/S
10.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.65
The company's EPS fell by 13% YoY and by 4.2% QoQ
The price to book (P/B) is 90% more than the 5-year quarterly average of 3.5 and 9% more than the last 4 quarters average of 6.1
The equity has plunged by 68% YoY and by 34% from the previous quarter
SCPH's price to sales (P/S) is 77% lower than its last 4 quarters average of 43.1
The revenue rose by 30% since the previous quarter

Efficiency

How efficient is scPharmaceuticals business performance
The company's return on sales has surged by 84% YoY and by 18% QoQ
SCPH's ROE has dropped by 80% year-on-year and by 36% since the previous quarter
The return on assets has declined by 31% year-on-year and by 18% since the previous quarter
scPharmaceuticals's return on invested capital has decreased by 18% QoQ but it has increased by 16% YoY

Dividends

What is SCPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SCPH.

Financial health

How did scPharmaceuticals financials performed over time
The company's total assets is 46% higher than its total liabilities
The company's quick ratio has shrunk by 66% YoY and by 15% QoQ
The current ratio has plunged by 62% YoY and by 12% from the previous quarter
SCPH's debt is 66% higher than its equity
The equity has plunged by 68% YoY and by 34% from the previous quarter
SCPH's debt to equity has surged by 54% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.